Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.68 |
| ▸ | POLB | P06746 | 7/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15409279 | 0.95 | TP53 (0.77) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411288 | 0.94 | MAPT (0.67) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411762 | 0.92 | TP53 (0.65) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411596 | 0.92 | MAPT (0.64) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15411614 | 0.90 | RXFP1 (0.70) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15409599 | 0.89 | TP53 (0.77) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL1075669 | 0.87 | MAPT (0.88) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15409235 | 0.86 | RXFP1 (0.63) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL15410324 | 0.84 | THRB (0.77) | MAPTTP53RXFP1POLBSMN1; SMN2 | |
| SCHEMBL1074474 | 0.82 | MAPT (1.00) | MAPTTP53RXFP1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | PRONOXIS AB (SE) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018384-A1 | QUINOLINONE DERIVATIVES FOR USE IN THE TREATMENT OF AN AUTOIMMUNE DISEASE AND/OR AN INFLAMMATORY DISEASE | NOX4, NOX1, CYBB | MAPT 2698/4885TP53 2443/4885RXFP1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.